SCHEMBL9895065

SCHEMBL9895065

COCC(=O)N1CCC(NC(=O)c2c(C)[nH]c3c(-c4cc(C)ccc4OCC4CC4)nc(C)nc23)CC1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 4/20 0.36
KDM2B Q8NHM5 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
LMNA P02545 3/20 0.35
POLB P06746 1/20 0.35
MAPK1 P28482 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NPY5R Q15761 2/20 0.34
KMT2A Q03164 2/20 0.33
RBP4 P02753 1/20 0.33
TTR P02766 1/20 0.33
MEN1 O00255 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
BRD4 O60885 2/20 0.33
GLA P06280 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
HPGD P15428 1/20 0.33
BTK Q06187 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9897480 0.94 KDM2B (0.36) KDM2BKDM4CLMNAPOLBMAPK1
SCHEMBL9896917 0.93 EPHX2 (0.39) KDM2BKDM4CLMNAPOLBMAPK1
SCHEMBL9898094 0.91 KDM2B (0.38) KDM2BKDM4CLMNAPOLBMAPK1
SCHEMBL9895934 0.91 KDM2B (0.37) KDM2BKDM4CLMNAPOLBMAPK1
SCHEMBL9898121 0.91 KDM2B (0.36) KDM2BKDM4CLMNAPOLBMAPK1
SCHEMBL9898079 0.88 KDM2B (0.35) KDM2BKDM4CLMNAPOLBMAPK1
SCHEMBL1441956 0.88 MAPK1 (0.34) SOS1LMNAPOLBMAPK1L3MBTL1
SCHEMBL9898632 0.88 PARP1 (0.42) LMNAPOLBMAPK1L3MBTL1KMT2A
SCHEMBL9101701 0.87 KDM2B (0.38) KDM2BKDM4CLMNAPOLBMAPK1
Hydrochloric Acid SCHEMBL9896017 0.86 KDM2B (0.36) KDM2BKDM4CLMNABRD4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470536-B1 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2014-11-12 EP claimed
US-20120149721-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES NYCOMED GMBH (DE) 2012-06-14 US claimed
US-9376442-B2 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2016-06-28 US disclosed
US-20150073001-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES ASTRAZENECA AB (SE) 2015-03-12 US disclosed
US-8927557-B2 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2015-01-06 US disclosed
EP-2470536-B1 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2014-11-12 EP disclosed
US-20120149721-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES NYCOMED GMBH (DE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149721-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES PDE5A, PDE12, PDE4A SOS1 4257/4885KDM2B 326/4885KDM4C 161/4885
US-20150073001-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES PDE12, PDE5A, PDE4A SOS1 3988/4885KDM2B 325/4885KDM4C 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.